Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Rigel Pharmaceuticals (RIGL) PT Raised to $49 at Citi
November 11, 2024 6:59 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $49.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "Gavreto posted an unexpectedly strong quarter with $7.1M in sales (driven by demand not stocking) vs. our/consensus ests of... More
